MEI Pharma, Inc.
(NASDAQ : MEIP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
4.92%15.151.8%$165.06m
VRXValeant Pharmaceuticals International, Inc.
2.01%21.3014.1%$125.33m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.83%154.196.2%$81.03m
PRGOPerrigo Co. Plc
1.05%46.156.8%$70.07m
SAGESAGE Therapeutics, Inc.
0.60%162.008.6%$61.94m
JAZZJazz Pharmaceuticals Plc
2.62%134.832.3%$54.72m
HZNPHorizon Pharma plc
0.60%27.006.7%$46.88m
UTHRUnited Therapeutics Corporation
2.33%81.3714.3%$44.61m
PTLAPortola Pharmaceuticals, Inc.
-0.36%30.417.5%$42.98m
ICLRICON Plc
1.32%157.174.1%$40.19m
ICPTIntercept Pharmaceuticals, Inc.
-0.99%64.0017.2%$38.64m
CTLTCatalent Inc
1.10%55.882.4%$35.42m
MDCOMedicines Company
3.78%32.7120.3%$33.51m
AERIAerie Pharmaceuticals, Inc.
-5.62%23.196.8%$25.01m
PCRXPacira Pharmaceuticals, Inc.
-1.85%38.2210.5%$24.00m

Company Profile

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.